Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.

Abstract

BACKGROUND In 2007, the Agency for Healthcare Research and Quality (AHRQ) published a comparative effectiveness review (CER) on the benefits and risks of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) for treating essential hypertension in adults. The main findings indicated that the 2 classes of… (More)

Topics

Cite this paper

@article{Powers2011UpdatesOT, title={Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.}, author={Benjamin J. Powers and Laurence S Greene and Lisa M Balfe}, journal={Journal of managed care pharmacy : JMCP}, year={2011}, volume={17 8 Suppl}, pages={S1-14} }